News
Sarepta shares slump after report of patient death in early-stage study
Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies has died from acute liver failure.
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...
Sarepta stock surged after the pharma company said it would lay off a third of its workforce and add a black-box warning to ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback